Live Meetings

Past Meetings

  • AWIR: Immunology Bootcamp

    Held in conjunction with the AWIR2017 Annual Meeting

    Immune-mediated inflammatory disease (IMID) is a group of clinically heterogenous disorders that share common immunopathology. The continued evaluation and refinement of biologic therapies in the treatment of IMIDs have provided significant benefit to patients suffering from these diseases. However, recognizing the underlying immunopathological mechanisms of these diseases is essential for understanding how current and emerging biologics exert their effects. Overall immune health has also been demonstrated to be influenced by exercise, mental health, diet, and lifestyle changes. In this CME educational activity, held during the Association of Women in Rheumatology National Conference, experts in the field will provide review and discussion of the immune system and practical approaches for immune health, as well as conduct a mini biologics summit, with a focus on rheumatology.

    • Thursday, August 17, 2017
      7:00 am – 1:45 pm
      Sonesta Resort Hilton Head Island
      Hilton Head, SC
  • RA Forum®: The Role of the Immune System in Disease Pathology and Treatment

    Rheumatoid arthritis (RA) is a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joints, leading to joint destruction, debility, and deformity. Increased understanding of the underlying pathophysiology of RA has made a remarkable difference in its treatment and prognosis. Numerous therapeutic agents with diverse targets and mechanisms have been added to the RA armamentarium, allowing for intervention at various stages in the pathogenic process of the disease. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as the efficacy profiles of current and emerging therapies. In this RA Forum®, leading rheumatologists will integrate discussions of basic immunologic principles with current and emerging RA treatments and interactive cases, as well as discuss treatment guidelines and use of biosimilars in the clinic.

     

  • Giant Cell Arteritis: Overcoming the Limitations of Conventional Agents with Biologic Therapy

    This is not an official program of the American College of Rheumatology. This symposium will be conducted during the 2017 ACR/ARHP Annual Meeting.

    The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new therapies are associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatologists are likely to encounter a wide variety of irAEs as the use of immune checkpoint inhibitors expands in the treatment of several cancers. Thus, it is critical for rheumatologists to be aware of these complications to accurately diagnose and manage the toxicities of immune checkpoint inhibitors in collaboration with treating oncologists. In this CME activity, expert faculty will review the role of the immune system in tumor biology and the appropriate management of irAEs associated with immune checkpoint inhibitors. Case-based examples will illustrate best practices for recognizing and managing these adverse events.

     

    • Sunday, November 5, 2017
      6:30 pm – 8:30 pm
      Hilton San Diego Bayfront
      San Diego, CA
  • Rheumatic Immune-related Adverse Events: Multidisciplinary Perspectives on Recognition and Management

    This is not an official program of the American College of Rheumatology. This symposium will be conducted after the 2017 ACR/ARHP Annual Meeting.

    The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new therapies are associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatologists are likely to encounter a wide variety of irAEs as the use of immune checkpoint inhibitors expands in the treatment of several cancers. Thus, it is critical for rheumatologists to be aware of these complications to accurately diagnose and manage the toxicities of immune checkpoint inhibitors in collaboration with treating oncologists. In this CME activity, expert faculty will review the role of the immune system in tumor biology and the appropriate management of irAEs associated with immune checkpoint inhibitors. Case-based examples will illustrate best practices for recognizing and managing these adverse events.

     

    • Wednesday, November 8, 2017
      1:00 pm – 3:00 pm
      Hilton San Diego Bayfront
      San Diego, CA
  • RA Forum™ 2016 CME Meeting Series:

    This exciting meeting series for rheumatologists will feature world-renowned specialists who will discuss the latest advancements in the immunologic mechanisms involved in the pathogenesis and treatment of rheumatoid arthritis (RA). Faculty will evaluate challenging questions surrounding theories of underlying biologic pathways driving autoimmunity and their implications in the discovery of new pharmacologic targets. Mechanisms of autoimmunity and inflammation will be compared to the emerging role of checkpoint therapy and small molecules in novel treatment approaches, including toxicity, efficacy, and safety.

     

  • Rheumatology Nursing Society: Immunology Bootcamp

    Held in conjunction with the 9th Rheumatology Nurses Society (RNS) Annual Conference

    Rheumatoid arthritis (RA) is a progressive, painful, systemic inflammatory disease that attacks the synovium of the joint, leading to joint destruction, debility, and deformity. If RA is not treated, it can cause diminished quality of life, loss of physical function, and difficulty carrying out the tasks of daily life. An increased understanding of immune-mediated pathways has led to the development of targeted RA therapies that have made significant differences in the treatment and prognosis of the disease. The introduction of biologic and other targeted therapies has changed the landscape of RA treatment and is also changing the nature of rheumatology nursing. Rheumatology nurses are challenged to keep up to date with these new and emerging therapies if they are to offer their patients care that will restore their optimal state of health and quality of life. This activity will focus on the principles of innate and adaptive immunity as they contribute to the pathophysiologic basis of RA, the clinical and immunologic progression of RA, the mechanism of action of biologics and immunosuppressive agents, and their adverse event profiles.

    • Wednesday, August 3, 2016
      1:00 pm – 5:00 pm
      Hilton Cleveland Downtown
      Cleveland, Ohio
  • Annual Rheumatology & Therapeutics Review for Organizations & Societies (ARTHROS) CME Meeting Series


Copyright © Vindico Medical Education | Privacy Policy

856.994.9400 | 6900 Grove Road, Building 100 | Thorofare, New Jersey 08086